CN116555134A - 产苏氨酸菌株的构建方法 - Google Patents
产苏氨酸菌株的构建方法 Download PDFInfo
- Publication number
- CN116555134A CN116555134A CN202210112879.3A CN202210112879A CN116555134A CN 116555134 A CN116555134 A CN 116555134A CN 202210112879 A CN202210112879 A CN 202210112879A CN 116555134 A CN116555134 A CN 116555134A
- Authority
- CN
- China
- Prior art keywords
- microorganism
- threonine
- dehydrogenase
- enzyme
- enhanced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004473 Threonine Substances 0.000 title claims abstract description 73
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 238000010276 construction Methods 0.000 title abstract description 26
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims abstract description 108
- 101710088194 Dehydrogenase Proteins 0.000 claims abstract description 56
- 108010064711 Homoserine dehydrogenase Proteins 0.000 claims abstract description 56
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims abstract description 51
- 108010055400 Aspartate kinase Proteins 0.000 claims abstract description 28
- 230000014509 gene expression Effects 0.000 claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 26
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 17
- 230000037361 pathway Effects 0.000 claims abstract description 17
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 16
- 108010022394 Threonine synthase Proteins 0.000 claims abstract description 15
- 102000006843 Threonine synthase Human genes 0.000 claims abstract description 15
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 claims abstract description 15
- 108010071598 homoserine kinase Proteins 0.000 claims abstract description 15
- 108020004652 Aspartate-Semialdehyde Dehydrogenase Proteins 0.000 claims abstract description 13
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims abstract description 8
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 59
- 244000005700 microbiome Species 0.000 claims description 40
- 230000000694 effects Effects 0.000 claims description 37
- 102000004190 Enzymes Human genes 0.000 claims description 34
- 108090000790 Enzymes Proteins 0.000 claims description 34
- 239000013612 plasmid Substances 0.000 claims description 28
- 241000186226 Corynebacterium glutamicum Species 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 18
- 210000000349 chromosome Anatomy 0.000 claims description 16
- 150000001413 amino acids Chemical group 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 102000003929 Transaminases Human genes 0.000 claims description 5
- 108090000340 Transaminases Proteins 0.000 claims description 5
- 229940024606 amino acid Drugs 0.000 claims description 4
- -1 aspartyl Chemical group 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 230000003313 weakening effect Effects 0.000 claims description 4
- 241000186031 Corynebacteriaceae Species 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000002744 homologous recombination Methods 0.000 claims description 2
- 230000006801 homologous recombination Effects 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000002703 mutagenesis Methods 0.000 claims description 2
- 231100000350 mutagenesis Toxicity 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 238000002741 site-directed mutagenesis Methods 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 241000186216 Corynebacterium Species 0.000 abstract description 7
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 64
- 229960002898 threonine Drugs 0.000 description 57
- 239000002609 medium Substances 0.000 description 35
- 238000012408 PCR amplification Methods 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 25
- 101150049887 cspB gene Proteins 0.000 description 18
- 101150041068 cspJ gene Proteins 0.000 description 18
- 101150010904 cspLB gene Proteins 0.000 description 18
- 229930006000 Sucrose Natural products 0.000 description 16
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 16
- 210000004556 brain Anatomy 0.000 description 16
- 238000001802 infusion Methods 0.000 description 16
- 239000005720 sucrose Substances 0.000 description 16
- 239000012634 fragment Substances 0.000 description 15
- 238000000855 fermentation Methods 0.000 description 13
- 230000004151 fermentation Effects 0.000 description 13
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 11
- 230000004927 fusion Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000010367 cloning Methods 0.000 description 8
- 238000004520 electroporation Methods 0.000 description 8
- 229930027917 kanamycin Natural products 0.000 description 8
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 8
- 229960000318 kanamycin Drugs 0.000 description 8
- 229930182823 kanamycin A Natural products 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 238000013207 serial dilution Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 101100462488 Phlebiopsis gigantea p2ox gene Proteins 0.000 description 6
- 235000012182 cereal bars Nutrition 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 101150060030 poxB gene Proteins 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 230000001131 transforming effect Effects 0.000 description 6
- 101150063051 hom gene Proteins 0.000 description 5
- 101150035025 lysC gene Proteins 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 101150072448 thrB gene Proteins 0.000 description 4
- 101150000850 thrC gene Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 101100337176 Escherichia coli (strain K12) gltB gene Proteins 0.000 description 3
- 101100505027 Escherichia coli (strain K12) gltD gene Proteins 0.000 description 3
- 101100057034 Talaromyces wortmannii astB gene Proteins 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 101150070145 aspB gene Proteins 0.000 description 3
- 101150100742 dapL gene Proteins 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 150000004728 pyruvic acid derivatives Chemical class 0.000 description 3
- 238000011426 transformation method Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 235000010633 broth Nutrition 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 101150097303 glyA gene Proteins 0.000 description 2
- 101150079604 glyA1 gene Proteins 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- VUUZLZXGRRDWBP-AAZKHNGSSA-N (2s,3r)-2-azanyl-3-oxidanyl-butanoic acid Chemical compound C[C@@H](O)[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O VUUZLZXGRRDWBP-AAZKHNGSSA-N 0.000 description 1
- HOSWPDPVFBCLSY-UHFFFAOYSA-N 2-azaniumyl-4-oxobutanoate Chemical compound OC(=O)C(N)CC=O HOSWPDPVFBCLSY-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000424760 Corynebacterium crenatum Species 0.000 description 1
- 102000002667 Glycine hydroxymethyltransferase Human genes 0.000 description 1
- 108010043428 Glycine hydroxymethyltransferase Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940085298 biotin 10 mg Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 241000186254 coryneform bacterium Species 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000019525 primary metabolic process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1217—Phosphotransferases with a carboxyl group as acceptor (2.7.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01003—Homoserine dehydrogenase (1.1.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
- C12Y102/01011—Aspartate-semialdehyde dehydrogenase (1.2.1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/05—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with a quinone or similar compound as acceptor (1.2.5)
- C12Y102/05001—Pyruvate dehydrogenase (quinone) (1.2.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y206/00—Transferases transferring nitrogenous groups (2.6)
- C12Y206/01—Transaminases (2.6.1)
- C12Y206/01021—D-Amino-acid transaminase (2.6.1.21), i.e. D-alanine aminotransferase/transaminase or D-aspartic aminotransferase/transaminase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/02—Phosphotransferases with a carboxy group as acceptor (2.7.2)
- C12Y207/02004—Aspartate kinase (2.7.2.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/03—Carbon-oxygen lyases (4.2) acting on phosphates (4.2.3)
- C12Y402/03001—Threonine synthase (4.2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/15—Corynebacterium
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明提供一种产苏氨酸菌株的构建方法。本发明将丙酮酸醌脱氢酶失活菌株(棒杆菌)应用于苏氨酸生产,其苏氨酸的产量较未改造菌株最多可提高25%~45.8%。进一步将其与苏氨酸合成路径中的天冬氨酸激酶、高丝氨酸脱氢酶、天冬氨酸半醛脱氢酶、天冬氨酸氨基转移酶、高丝氨酸激酶、苏氨酸合酶等中的至少一个表达强化相组合时,苏氨酸的产量均有10~21倍的提升。为大规模生产苏氨酸提供了新途径,具有较高的应用价值。
Description
技术领域
本发明属于微生物工程技术领域,具体地说,涉及一种产苏氨酸菌株的构建方法。
背景技术
L-苏氨酸(L-Threonin),化学名称为β-羟基-α-氨基丁酸,分子式为C4H9NO3,相对分子质量为119.12。L-苏氨酸是一种必需的氨基酸,苏氨酸主要用于医药、化学试剂、食品强化剂、饲料添加剂等方面。
谷氨酸棒杆菌中,由草酰乙酸生成苏氨酸需要五步催化反应,分别为天冬氨酸激酶(lysC编码)、天冬氨酸半醛脱氢酶(asd编码)、高丝氨酸脱氢酶(hom编码)、高丝氨酸激酶(thrB)以及苏氨酸合酶(thrC)编码。Hermann Sahm等人一直致力于高产苏氨酸的谷棒菌株的开发,并取得一定突破,获得了抗反馈抑制的hom基因(Reinscheid D J,Eikmanns B J,Sahm H.Analysis of a Corynebacterium glutamicum hom gene coding for afeedback-resistant homoserine dehydrogenase.[J].Journal of Bacteriology,1991,173(10):3228-3230)、lysC基因(Eikmanns B J,Eggeling L,Sahm H.Molecular aspectsof lysine,threonine,and isoleucine biosynthesis in Corynebacteriumglutamicum.[J].Antonie Van Leeuwenhoek,1993,64(2):145-163)。继Hermann Sahm之后,Lothar Eggling在该领域进行了进一步的探索,弱化苏氨酸利用途径中的编码基因glyA,同时过表达苏氨酸外运蛋白ThrE,使得苏氨酸的产量由49mM提高到67mM(Simic P,Willuhn J,Sahm H,et al.Identification of glyA(Encoding SerineHydroxymethyltransferase)and Its Use Together with the Exporter ThrE ToIncrease l-Threonine Accumulation by Corynebacterium glutamicum[J].Appliedand Environmental Microbiology,2002,68(7):3321-3327)。
目前利用谷氨酸棒状杆菌生产苏氨酸的报道主要集中在其合成路径中,TCA循环及中央代谢等方面的报道较少。且现有报道仅对苏氨酸合成路径做了初步研究,并未形成系统。
发明内容
本发明的目的是通过失活丙酮酸醌脱氢酶使菌株生产苏氨酸的能力得到提升,从而提供一种产苏氨酸(L-苏氨酸)菌株的构建方法。
为了实现本发明目的,第一方面,本发明提供一种修饰的棒状杆菌属微生物,所述微生物相比于未修饰的微生物,其丙酮酸醌脱氢酶的活性降低或丧失,且所述微生物相比于未修饰的微生物具有增强的苏氨酸生产能力。优选地,丙酮酸醌脱氢酶在NCBI上的参考序列编号为WP_011015247.1,或与其相似性为90%的氨基酸序列。
进一步地,所述微生物体内丙酮酸醌脱氢酶的活性降低或丧失是通过降低编码丙酮酸醌脱氢酶基因的表达或敲除内源的编码丙酮酸醌脱氢酶的基因来实现的。
可以采用诱变、定点突变或同源重组等方法来降低编码丙酮酸醌脱氢酶基因的表达或敲除内源的编码丙酮酸醌脱氢酶的基因。
进一步地,所述微生物与未修饰的微生物相比,其体内苏氨酸合成途径相关的酶的活性增强;
其中,所述与苏氨酸合成途径相关的酶选自天冬氨酸激酶、高丝氨酸脱氢酶、天冬氨酸半醛脱氢酶、天冬氨酸氨基转移酶、高丝氨酸激酶、苏氨酸合酶中的至少一种;优选地,它们在NCBI上的参考序列编号分别为WP_003855724.1、WP_003854900.1、WP_011013506.1、WP_011013497.1、WP_011014183.1、WP_011014964.1,或与上述参考序列相似度为90%的氨基酸序列。
优选地,所述微生物为如下①~⑤中的任一种:
①丙酮酸醌脱氢酶活性降低或丧失且天冬氨酸激酶和/或高丝氨酸脱氢酶活性增强的微生物;
②丙酮酸醌脱氢酶活性降低或丧失且天冬氨酸激酶、高丝氨酸脱氢酶和/或天冬氨酸氨基转移酶活性增强的微生物;
③丙酮酸醌脱氢酶活性降低或丧失且天冬氨酸激酶、高丝氨酸脱氢酶和/或天冬氨酸半醛脱氢酶活性增强的微生物;
④丙酮酸醌脱氢酶活性降低或丧失且天冬氨酸激酶、高丝氨酸脱氢酶和/或高丝氨酸激酶活性增强的微生物;
⑤丙酮酸醌脱氢酶活性降低或丧失且天冬氨酸激酶、高丝氨酸脱氢酶和/或苏氨酸合酶活性增强的微生物。
所述微生物体内苏氨酸合成途径相关的酶的活性的增强是由选自以下1)~6),或任选的组合实现的:
1)通过导入具有所述酶的编码基因的质粒而增强;
2)通过增加染色体上所述酶的编码基因的拷贝数而增强;
3)通过改变染色体上所述酶的编码基因的启动子序列而增强;
4)通过将强启动子与所述酶的编码基因可操作地连接而增强;
5)通过对酶的氨基酸序列进行改变而增强;
6)通过对编码酶的核苷酸序列进行改变而增强。
优选地,本发明所述棒杆菌为谷氨酸棒状杆菌(Corynebacterium glutamicum),谷氨酸棒状杆菌包括ATCC13032、ATCC13870、ATCC13869、ATCC21799、ATCC21831、ATCC14067、ATCC13287等(参见NCBI Corunebacterium glutamicum进化树https://www.ncbi.nlm.nih.gov/genome/469),更优选谷氨酸棒状杆菌ATCC 13032。
第二方面,本发明提供产苏氨酸菌株的构建方法,所述方法包括:
A、弱化具有氨基酸生产能力的棒杆菌中编码丙酮酸醌脱氢酶的基因,获得基因弱化菌株;所述弱化包括敲除或降低丙酮酸醌脱氢酶编码基因的表达;和/或
B、增强步骤A基因弱化菌株中与苏氨酸合成途径相关的酶,获得酶活增强菌株;
所述增强的途径选自以下1)~5),或任选的组合:
1)通过导入具有所述酶的编码基因的质粒而增强;
2)通过增加染色体上所述酶的编码基因的拷贝数而增强;
3)通过改变染色体上所述酶的编码基因的启动子序列而增强;
4)通过将强启动子与所述酶的编码基因可操作地连接而增强;
5)通过对酶的氨基酸序列进行改变而增强。
第三方面,本发明提供一种生产苏氨酸的方法,所述方法包括如下步骤:
a)培养所述修饰的棒状杆菌属微生物,以获得所述微生物的培养物;
b)从步骤a)中获得的所述培养物中收集所产生的苏氨酸。
第四方面,本发明提供编码丙酮酸醌脱氢酶的基因的敲除或降低表达在苏氨酸发酵生产或提高苏氨酸发酵产量中的应用。
进一步地,通过失活具有氨基酸生产能力的棒杆菌(Corynebacterium)中的丙酮酸醌脱氢酶来提高苏氨酸的发酵产量。
优选地,本发明所述棒杆菌为谷氨酸棒状杆菌(Corynebacterium glutamicum),谷氨酸棒状杆菌包括ATCC13032、ATCC13870、ATCC13869、ATCC21799、ATCC21831、ATCC14067、ATCC13287等(参见NCBI Corunebacterium glutamicum进化树https://www.ncbi.nlm.nih.gov/genome/469),更优选谷氨酸棒状杆菌ATCC 13032。
第五方面,本发明提供所述修饰的棒状杆菌属微生物或按照上述方法构建得到的产苏氨酸菌株在苏氨酸发酵生产或提高苏氨酸发酵产量中的应用。
上述有关菌株的改造方法包括基因的强化和弱化等均为本领域技术人员可知的改造方式,参见满在伟.高产L-精氨酸钝齿棒杆菌的系统途径工程改造[D].江南大学,2016;崔毅.代谢工程改造谷氨酸棒杆菌生产L--亮氨酸[D].天津科技大学.;徐国栋.L-异亮氨酸生产菌株的构建及发酵条件优化.天津科技大学,2015.
借由上述技术方案,本发明至少具有下列优点及有益效果:
本发明将丙酮酸醌脱氢酶失活菌株(棒杆菌,如谷氨酸棒状杆菌)应用于苏氨酸生产,其苏氨酸的产量较未改造菌株最多可提高25%~45.8%。进一步将其与苏氨酸合成路径中的天冬氨酸激酶、高丝氨酸脱氢酶、天冬氨酸半醛脱氢酶、天冬氨酸氨基转移酶、高丝氨酸激酶、苏氨酸合酶等中的至少一个表达强化相组合时,苏氨酸的产量均有10~21倍的提升。为大规模生产苏氨酸提供了新途径,具有较高的应用价值。
具体实施方式
本发明重点考察了丙酮酸醌脱氢酶失活对苏氨酸生产的影响,在谷氨酸棒状杆菌ATCC 13032菌株的基础上失活丙酮酸醌脱氢酶的编码基因,得到菌株SMCT322,苏氨酸含量为0.2g/L。可见,丙酮酸醌脱氢酶活性丢失有利于苏氨酸的生产。
在此基础上,为了进一步验证丙酮酸醌脱氢酶活性丢失对苏氨酸生产的影响,对菌株的苏氨酸合成路径进一步强化,主要包括天冬氨酸激酶、高丝氨酸脱氢酶、天冬氨酸半醛脱氢酶、天冬氨酸氨基转移酶、高丝氨酸激酶、苏氨酸合酶至少一个表达强化或解调控。从摇瓶结果可以看出所有生产苏氨酸的菌株在丙酮酸醌脱氢酶活性丢失后,其苏氨酸的生产能力有所提升;同时与仅失活编码丙酮酸醌脱氢酶编码基因的菌株相比,丙酮酸醌脱氢酶活性丢失和苏氨酸合成路径中的酶表达强化相结合的菌株其苏氨酸的生产上更有优势。
改造过程中的失活或弱化包括启动子的替换,核糖体结合位点的改变、点突变、序列的缺失等手段,改造过程中的表达强化包括启动子的替换,核糖体结合位点的改变、拷贝数的增加、质粒过表达等手段,且以上手段均为本领域研究人员公知手段。以上手段无法通过举例而穷尽,具体实施例中仅以启动子强化作为代表进行说明。
本发明采用如下技术方案:
本发明的技术方案之一,提供一种利用丙酮酸醌脱氢酶活性丢失菌株生产苏氨酸的方法。
本发明的技术方案之二,提供一种利用丙酮酸醌脱氢酶失活及天冬氨酸激酶、高丝氨酸脱氢酶、天冬氨酸半醛脱氢酶、高丝氨酸激酶、苏氨酸合酶至少一个表达强化或解调控表达强化的菌株生产苏氨酸的方法。
本发明的技术方案之三,提供一种利用丙酮酸醌脱氢酶失活及天冬氨酸激酶、高丝氨酸脱氢酶表达强化的菌株生产苏氨酸的方法。
本发明的技术方案之四,提供一种利用丙酮酸醌脱氢酶失活及天冬氨酸激酶、高丝氨酸脱氢酶、天冬氨酸氨基转移酶表达强化的菌株生产苏氨酸的方法。
本发明的技术方案之五,提供一种利用丙酮酸醌脱氢酶失活及天冬氨酸激酶、高丝氨酸脱氢酶、天冬氨酸半醛脱氢酶表达强化的菌株生产苏氨酸的方法。
本发明的技术方案之六,提供一种利用丙酮酸醌脱氢酶失活及天冬氨酸激酶、高丝氨酸脱氢酶、高丝氨酸激酶表达强化的菌株生产苏氨酸的方法。
本发明的技术方案之七,提供一种利用丙酮酸醌脱氢酶失活及天冬氨酸激酶、高丝氨酸脱氢酶、苏氨酸合酶表达强化的菌株生产苏氨酸的方法。
上述菌株为棒杆菌,优选谷氨酸棒状杆菌,最优选谷氨酸棒状杆菌ATCC 13032。
本发明涉及的蛋白的编码基因如下:
丙酮酸醌脱氢酶,编码基因poxB/pqo,NCBI编号:cg2891、cgl2610、NCgl2521。
天冬氨酸激酶,编码基因名称lysC,NCBI编号:cg0306、Cgl0251、NCgl0247。
天冬氨酸半醛脱氢酶,编码基因名称asd,NCBI编号:Cgl0252、Cg0307、NCgl0248。
高丝氨酸脱氢酶,编码基因名称hom,NCBI编号:Cg1337、Cgl1183、NCgl1136。
苏氨酸合酶,编码基因名称thrC,NCBI编号:cg2437、Cgl2220、NCgl2139。
高丝氨酸激酶,编码基因thrB,NCBI编号:cg1338、Cgl1184、NCgl1137。
天冬氨酸氨基转移酶,编码基因aspB,NCBI编号:cg0294、Cgl0240、NCgl0237。
以下实施例用于说明本发明,但不用来限制本发明的范围。若未特别指明,实施例均按照常规实验条件,如Sambrook等分子克隆实验手册(Sambrook J&Russell DW,Molecular Cloning:a Laboratory Manual,2001),或按照制造厂商说明书建议的条件。
以下实施例中使用的实验材料如下:
以下实施例中涉及的实验方法如下:
PCR扩增体系如下:
成分 | 体积(微升) |
灭菌的去离子水 | 29 |
5×pfu buffer | 10 |
2.5mM dNTP | 5 |
10μM上游引物 | 2 |
10μM下游引物 | 2 |
Pfu | 1 |
模板 | 1(融合PCR模板最大加到2微升) |
共计 | 50 |
PCR扩增程序如下:
菌株改造方法:
1、无缝组装反应程序:参照ClonExpress MultiS One Step Cloning Kit说明书。
2、转化方法:参照Trans1-T1 Phage Resistant Chemically Competent Cell说明书。
3、感受态细胞的制备:参照C.glutamicum Handbook,Charpter 23。
实施例1菌株基因组改造质粒的构建
1、丙酮酸醌脱氢酶失活方案重组质粒pK18mobsacB-△poxB的构建
以谷氨酸棒状杆菌ATCC 13032基因组为模板,以poxB1/poxB2引物对进行PCR扩增得到上游同源臂up,以poxB3/poxB4引物对进行PCR扩增得到下游同源臂dn,以poxB1/poxB4引物对以up、dn为模板进行融合PCR,获得全长片段△poxB。pK18mobsacB用BamHI/HindIII酶切。两者用无缝克隆试剂盒进行组装,转化Trans1 T1感受态细胞,获得重组质粒pK18mobsacB-△poxB。
2、天冬氨酸激酶表达强化方案重组质粒pK18mobsacB-Psod-lysCg1a-T311I的构建
以谷氨酸棒状杆菌ATCC 13032基因组为模板,以P21/P22引物对进行PCR扩增得到上游同源臂up,以P23/P24引物对进行PCR扩增得到启动子片段Psod,以P25/P26引物对进行PCR扩增得到lysCg1a-T311I,以P27/P28引物对进行PCR扩增得到下游同源臂dn。以P21/P24引物对以up、Psod为模板进行融合PCR,获得片段up-Psod。以P21/P28引物对以up-Psod、lysCg1a-T311I、dn为模板进行融合PCR获得全长片段up-Psod-lysCg1a-T311I-dn。pK18mobsacB用BamHI/HindIII酶切。两者用无缝克隆试剂盒进行组装,转化Trans1 T1感受态细胞,获得重组质粒pK18mobsacB-Psod-lysCg1a-T311I。
其中,g1a表示lysC基因(lysC野生型基因序列见SEQ ID NO:1)起始密码子的第1位碱基由g突变为a,T311I表示lysC基因编码的天冬氨酸激酶的第311为氨基酸由T突变为I。
3、高丝氨酸脱氢酶表达强化方案重组质粒pK18mobsacB-PcspB-homG378E的构建
以谷氨酸棒状杆菌ATCC 13032基因组为模板,以P29/P30引物对进行PCR扩增得到上游同源臂up,以ATCC14067基因组为模板以P31/P32引物对进行PCR扩增得到启动子片段PcspB,以ATCC13032基因组为模板以P33/P34引物对进行PCR扩增得到homG378E,以P35/P36引物对进行PCR扩增得到下游同源臂dn。以P29/P32引物对以up、PcspB为模板进行融合PCR,获得片段up-PcspB。以P29/P36引物对以up-PcspB、homG378E、dn为模板进行融合PCR获得全长片段up-PcspB-homG378E-dn。pK18mobsacB用BamHI/HindIII酶切。两者用无缝克隆试剂盒进行组装,转化Trans1 T1感受态细胞,获得重组质粒pK18mobsacB-PcspB-homG378E。
4、天冬氨酸半醛脱氢酶表达强化方案重组质粒pK18mobsacB-Psod-asd的构建
以谷氨酸棒状杆菌ATCC 13032基因组为模板,以P1/P2引物对进行PCR扩增得到上游同源臂up,以P3/P4引物对进行PCR扩增得到启动子片段Psod,以P5/P6引物对进行PCR扩增得到下游同源臂dn。以P1/P6引物对以up、Psod、dn为模板进行融合PCR获得全长片段up-Psod-dn。pK18mobsacB用BamHI/HindIII酶切。两者用无缝克隆试剂盒进行组装,转化Trans1 T1感受态细胞,获得重组质粒pK18mobsacB-Psod-asd。
5、天冬氨酸氨基转移酶表达强化方案重组质粒pK18mobsacB-Psod-aspB的构建
以谷氨酸棒状杆菌ATCC 13032基因组为模板,以P103/P104引物对进行PCR扩增得到上游同源臂up,以P105/P106引物对进行PCR扩增得到启动子片段Psod,以P107/P108引物对进行PCR扩增得到下游同源臂dn。以P103/P108引物对以up、Psod、dn为模板进行融合PCR获得全长片段up-Psod-dn。pK18mobsacB用BamHI/HindIII酶切。两者用无缝克隆试剂盒进行组装,转化Trans1 T1感受态细胞,获得重组质粒pK18mobsacB-Psod-aspB。
6、高丝氨酸激酶表达强化方案重组质粒pK18-PcspB-thrB的构建
以谷氨酸棒状杆菌ATCC 13032基因组为模板,以P7/P8引物对进行PCR扩增得到上游同源臂up,以ATCC14067基因组为模板以P9/P10引物对进行PCR扩增得到启动子片段PcspB,以ATCC13032基因组为模板以P11/P12引物对进行PCR扩增得到下游同源臂dn。以P7/P12引物对以up、PcspB、dn为模板进行融合PCR获得全长片段up-PcspB-dn。pK18mobsacB用BamHI/HindIII酶切。两者用无缝克隆试剂盒进行组装,转化Trans1 T1感受态细胞,获得重组质粒pK18-PcspB-thrB。
7、苏氨酸合酶表达强化质粒pK18mobsacB-Psod-thrCg1a的构建
以谷氨酸棒状杆菌ATCC 13032基因组为模板,以P37/P38引物对进行PCR扩增得到上游同源臂up,以P39/P40引物对进行PCR扩增得到启动子片段Psod-thrCg1a,以P41/P42引物对进行PCR扩增得到下游同源臂dn。以P37/P42引物对以up、Psod-thrCg1a、dn为模板进行融合PCR获得全长片段up-Psod-thrCg1a-dn。pK18mobsacB用BamHI/HindIII酶切。两者用无缝克隆试剂盒进行组装,转化Trans1 T1感受态细胞,获得重组质粒pK18mobsacB-Psod-thrCg1a。
其中,g1a表示thrC基因(thrC野生型基因序列见SEQ ID NO:2)起始密码子的第1位碱基由g突变为a。构建过程中所用引物如表1所示:
表1
注:加粗字体及下划线为引入相应点突变的引物。
实施例2基因组改造菌株的构建
1、丙酮酸醌脱氢酶失活菌株的构建
按照谷棒经典方法(C.glutamicum Handbook,Charpter 23)制备ATCC13032感受态细胞。重组质粒pK18mobsacB-△poxB以电穿孔方法转化该感受态细胞,并在含有15mg/L卡那霉素的选择培养基上筛选转化子,其中感兴趣的基因由于同源性被插入到染色体中。将筛得的转化子过夜培养于普通液体脑心浸液培养基中,培养温度为30℃,回转摇床220rpm振荡培养。此培养过程中,转化子发生第二次重组,通过基因交换将载体序列从基因组中除去。将培养物做连续梯度稀释(10-2连续稀释至10-4),稀释液涂布在含有10%蔗糖的普通固体脑心浸液培养基上,33℃静置培养48h。蔗糖培养基上长出的菌株在其基因组中不携带插入的载体序列。通过PCR扩增目的序列,核苷酸测序分析,获得目的突变菌株命名为SMCT322。
2、天冬氨酸激酶强化表达及解调控菌株的构建
按照谷棒经典方法(C.glutamicum Handbook,Charpter 23)制备ATCC13032感受态细胞。重组质粒pK18mobsacB-Psod-lysCg1a-T311I以电穿孔方法转化该感受态细胞,并在含有15mg/L卡那霉素的选择培养基上筛选转化子,其中感兴趣的基因由于同源性被插入到染色体中。将筛得的转化子过夜培养于普通液体脑心浸液培养基中,培养温度为30℃,回转摇床220rpm振荡培养。此培养过程中,转化子发生第二次重组,通过基因交换将载体序列从基因组中除去。将培养物做连续梯度稀释(10-2连续稀释至10-4),稀释液涂布在含有10%蔗糖的普通固体脑心浸液培养基上,33℃静置培养48h。蔗糖培养基上长出的菌株在其基因组中不携带插入的载体序列。通过PCR扩增目的序列,核苷酸测序分析,获得目的突变菌株命名为SMCT323。
3、高丝氨酸脱氢酶表达强化菌株的构建
按照谷棒经典方法(C.glutamicum Handbook,Charpter 23)制备SMCT323感受态细胞。重组质粒pK18mobsacB-PcspB-homG378E以电穿孔方法转化该感受态细胞,并在含有15mg/L卡那霉素的选择培养基上筛选转化子,其中感兴趣的基因由于同源性被插入到染色体中。将筛得的转化子过夜培养于普通液体脑心浸液培养基中,培养温度为30℃,回转摇床220rpm振荡培养。此培养过程中,转化子发生第二次重组,通过基因交换将载体序列从基因组中除去。将培养物做连续梯度稀释(10-2连续稀释至10-4),稀释液涂布在含有10%蔗糖的普通固体脑心浸液培养基上,33℃静置培养48h。蔗糖培养基上长出的菌株在其基因组中不携带插入的载体序列。通过PCR扩增目的序列,核苷酸测序分析,获得目的突变菌株命名为SMCT324。
4、天冬氨酸半醛脱氢酶表达强化菌株的构建
按照谷棒经典方法(C.glutamicum Handbook,Charpter 23)制备SMCT324感受态细胞。重组质粒pK18mobsacB-Psod-asd以电穿孔方法转化该感受态细胞,并在含有15mg/L卡那霉素的选择培养基上筛选转化子,其中感兴趣的基因由于同源性被插入到染色体中。将筛得的转化子过夜培养于普通液体脑心浸液培养基中,培养温度为30℃,回转摇床220rpm振荡培养。此培养过程中,转化子发生第二次重组,通过基因交换将载体序列从基因组中除去。将培养物做连续梯度稀释(10-2连续稀释至10-4),稀释液涂布在含有10%蔗糖的普通固体脑心浸液培养基上,33℃静置培养48h。蔗糖培养基上长出的菌株在其基因组中不携带插入的载体序列。通过PCR扩增目的序列,核苷酸测序分析,获得目的突变菌株命名为SMCT325。
5、天冬氨酸氨基转移酶表达强化菌株的构建
按照谷棒经典方法(C.glutamicum Handbook,Charpter 23)制备SMCT324感受态细胞。重组质粒pK18mobsacB-Psod-aspB以电穿孔方法转化该感受态细胞,并在含有15mg/L卡那霉素的选择培养基上筛选转化子,其中感兴趣的基因由于同源性被插入到染色体中。将筛得的转化子过夜培养于普通液体脑心浸液培养基中,培养温度为30℃,回转摇床220rpm振荡培养。此培养过程中,转化子发生第二次重组,通过基因交换将载体序列从基因组中除去。将培养物做连续梯度稀释(10-2连续稀释至10-4),稀释液涂布在含有10%蔗糖的普通固体脑心浸液培养基上,33℃静置培养48h。蔗糖培养基上长出的菌株在其基因组中不携带插入的载体序列。通过PCR扩增目的序列,核苷酸测序分析,获得目的突变菌株命名为SMCT326。
6、高丝氨酸激酶表达强化菌株的构建
按照谷棒经典方法(C.glutamicum Handbook,Charpter 23)制备SMCT324感受态细胞。重组质粒pK18-PcspB-thrB以电穿孔方法转化该感受态细胞,并在含有15mg/L卡那霉素的选择培养基上筛选转化子,其中感兴趣的基因由于同源性被插入到染色体中。将筛得的转化子过夜培养于普通液体脑心浸液培养基中,培养温度为30℃,回转摇床220rpm振荡培养。此培养过程中,转化子发生第二次重组,通过基因交换将载体序列从基因组中除去。将培养物做连续梯度稀释(10-2连续稀释至10-4),稀释液涂布在含有10%蔗糖的普通固体脑心浸液培养基上,33℃静置培养48h。蔗糖培养基上长出的菌株在其基因组中不携带插入的载体序列。通过PCR扩增目的序列,核苷酸测序分析,获得目的突变菌株命名为SMCT327。
7、苏氨酸合酶表达强化菌株的构建
按照谷棒经典方法(C.glutamicum Handbook,Charpter 23)制备SMCT324感受态细胞。重组质粒pK18mobsacB-Psod-thrCg1a以电穿孔方法转化该感受态细胞,并在含有15mg/L卡那霉素的选择培养基上筛选转化子,其中感兴趣的基因由于同源性被插入到染色体中。将筛得的转化子过夜培养于普通液体脑心浸液培养基中,培养温度为30℃,回转摇床220rpm振荡培养。此培养过程中,转化子发生第二次重组,通过基因交换将载体序列从基因组中除去。将培养物做连续梯度稀释(10-2连续稀释至10-4),稀释液涂布在含有10%蔗糖的普通固体脑心浸液培养基上,33℃静置培养48h。蔗糖培养基上长出的菌株在其基因组中不携带插入的载体序列。通过PCR扩增目的序列,核苷酸测序分析,获得目的突变菌株命名为SMCT328。
8、丙酮酸醌脱氢酶失活菌株的构建
按照谷棒经典方法(C.glutamicum Handbook,Charpter 23)制备SMCT324、SMCT325、SMCT326、SMCT327、SMCT328感受态细胞。重组质粒pK18mobsacB-△poxB以电穿孔方法转化该感受态细胞,并在含有15mg/L卡那霉素的选择培养基上筛选转化子,其中感兴趣的基因由于同源性被插入到染色体中。将筛得的转化子过夜培养于普通液体脑心浸液培养基中,培养温度为30℃,回转摇床220rpm振荡培养。此培养过程中,转化子发生第二次重组,通过基因交换将载体序列从基因组中除去。将培养物做连续梯度稀释(10-2连续稀释至10-4),稀释液涂布在含有10%蔗糖的普通固体脑心浸液培养基上,33℃静置培养48h。蔗糖培养基上长出的菌株在其基因组中不携带插入的载体序列。通过PCR扩增目的序列,核苷酸测序分析,获得目的突变菌株命名为SMCT329、SMCT330、SMCT331、SMCT332、SMCT333。获得的菌株如表2所示:
表2
菌株 | 基因型 |
SMCT322 | ATCC13032,ΔpoxB |
SMCT323 | ATCC13032,Psod-lysCg1a-T311I |
SMCT324 | ATCC13032,Psod-lysCg1a-T311I,PcspB-homG378E |
SMCT325 | ATCC13032,Psod-lysCg1a-T311I,PcspB-homG378E,Psod-asd |
SMCT326 | ATCC13032,Psod-lysCg1a-T311I,PcspB-homG378E,Psod-aspB |
SMCT327 | ATCC13032,Psod-lysCg1a-T311I,PcspB-homG378E,PcspB-thrB |
SMCT328 | ATCC13032,Psod-lysCg1a-T311I,PcspB-homG378E,Psod-thrCg1a |
SMCT329 | ATCC13032,Psod-lysCg1a-T311I,PcspB-homG378E,ΔpoxB |
SMCT330 | ATCC13032,Psod-lysCg1a-T311I,PcspB-homG378E,Psod-asd,ΔpoxB |
SMCT331 | ATCC13032,Psod-lysCg1a-T311I,PcspB-homG378E,Psod-aspB,ΔpoxB |
SMCT332 | ATCC13032,Psod-lysCg1a-T311I,PcspB-homG378E,PcspB-thrB,ΔpoxB |
SMCT333 | ATCC13032,Psod-lysCg1a-T311I,PcspB-homG378E,Psod-thrCg1a,ΔpoxB |
实施例3构建菌株摇瓶验证
1.培养基
种子活化培养基:BHI 3.7%,琼脂2%,pH7。
种子培养基:蛋白胨5/L,酵母抽提物5g/L,氯化钠10g/L,硫酸铵16g/L,尿素8g/L,磷酸二氢钾10.4g/L,磷酸氢二钾21.4g/L,生物素5mg/L,硫酸镁3g/L。葡萄糖50g/L,pH7.2。
发酵培养基:玉米浆50mL/L,葡萄糖30g/L,硫酸铵4g/L,MOPS 30g/L,磷酸二氢钾10g/L,尿素20g/L,生物素10mg/L,硫酸镁6g/L,硫酸亚铁1g/L,VB1·HCl 40mg/L,泛酸钙50mg/L,烟酰胺40mg/L,硫酸锰1g/L,硫酸锌20mg/L,硫酸铜20mg/L,pH 7.2。
2.工程菌摇瓶发酵生产L-苏氨酸
(1)种子培养:挑取SMCT181、SMCT182、SMCT183、SMCT184、SMCT185、SMCT186、SMCT187、SMCT188、SMCT189、SMCT190、SMCT191、SMCT192、SMCT193、SMCT194、SMCT195、SMCT196和SMCT197斜面种子1环接至装有20mL种子培养基的500mL三角瓶中,30℃、220r/min振荡培养16h。
(2)发酵培养:将2mL种子液接种至装有20mL发酵培养基的500mL三角瓶中,33℃、220r/min振荡培养24h。
(3)取1mL发酵液离心(12000rpm,2min),收集上清液,用HPLC检测工程菌与对照菌发酵液中的L-苏氨酸。
苏氨酸摇瓶发酵结果如表3所示:
表3
菌株编号 | OD562 | 苏氨酸(g/L) | 菌株编号 | OD562 | 苏氨酸(g/L) |
ATCC13032 | 25 | — | SMCT322 | 25 | 0.2 |
SMCT324 | 23 | 2.4 | SMCT329 | 23 | 3.5 |
SMCT325 | 23 | 2.8 | SMCT330 | 23 | 3.8 |
SMCT326 | 24 | 3.0 | SMCT331 | 24 | 4.1 |
SMCT327 | 24 | 3.2 | SMCT332 | 24 | 4.0 |
SMCT328 | 23 | 3.0 | SMCT333 | 23 | 4.2 |
由表3可以看出,丙酮酸醌脱氢酶失活后的菌株的苏氨酸产量较失活前有所提高,其产量提高在20.5%~45.8%之间,苏氨酸最高产量为4.2g/L。不同的丙酮酸醌脱氢酶失活菌株之间的苏氨酸产量有所差异,在0.2g/L~1.2g/L之间,说明丙酮酸醌脱氢酶的失活与不同位点的组合有不同的效果,且当其与苏氨酸合成路径中的天冬氨酸激酶、高丝氨酸脱氢酶、天冬氨酸半醛脱氢酶、天冬氨酸氨基转移酶、高丝氨酸激酶、苏氨酸合酶至少一个表达强化相组合时,其苏氨酸产量均有10~21倍的提升。
虽然,上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述,但在本发明基础上,可以对之做一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
序列表
<110> 廊坊梅花生物技术开发有限公司
<120> 产苏氨酸菌株的构建方法
<130> KHP211124123.7
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1266
<212> DNA
<213> 谷氨酸棒状杆菌(Corynebacterium glutamicum)
<400> 1
gtggccctgg tcgtacagaa atatggcggt tcctcgcttg agagtgcgga acgcattaga 60
aacgtcgctg aacggatcgt tgccaccaag aaggctggaa atgatgtcgt ggttgtctgc 120
tccgcaatgg gagacaccac ggatgaactt ctagaacttg cagcggcagt gaatcccgtt 180
ccgccagctc gtgaaatgga tatgctcctg actgctggtg agcgtatttc taacgctctc 240
gtcgccatgg ctattgagtc ccttggcgca gaagcccaat ctttcacggg ctctcaggct 300
ggtgtgctca ccaccgagcg ccacggaaac gcacgcattg ttgatgtcac tccaggtcgt 360
gtgcgtgaag cactcgatga gggcaagatc tgcattgttg ctggtttcca gggtgttaat 420
aaagaaaccc gcgatgtcac cacgttgggt cgtggtggtt ctgacaccac tgcagttgcg 480
ttggcagctg ctttgaacgc tgatgtgtgt gagatttact cggacgttga cggtgtgtat 540
accgctgacc cgcgcatcgt tcctaatgca cagaagctgg aaaagctcag cttcgaagaa 600
atgctggaac ttgctgctgt tggctccaag attttggtgc tgcgcagtgt tgaatacgct 660
cgtgcattca atgtgccact tcgcgtacgc tcgtcttata gtaatgatcc cggcactttg 720
attgccggct ctatggagga tattcctgtg gaagaagcag tccttaccgg tgtcgcaacc 780
gacaagtccg aagccaaagt aaccgttctg ggtatttccg ataagccagg cgaggctgcg 840
aaggttttcc gtgcgttggc tgatgcagaa atcaacattg acatggttct gcagaacgtc 900
tcttctgtag aagacggcac caccgacatc accttcacct gccctcgttc cgacggccgc 960
cgcgcgatgg agatcttgaa gaagcttcag gttcagggca actggaccaa tgtgctttac 1020
gacgaccagg tcggcaaagt ctccctcgtg ggtgctggca tgaagtctca cccaggtgtt 1080
accgcagagt tcatggaagc tctgcgcgat gtcaacgtga acatcgaatt gatttccacc 1140
tctgagattc gtatttccgt gctgatccgt gaagatgatc tggatgctgc tgcacgtgca 1200
ttgcatgagc agttccagct gggcggcgaa gacgaagccg tcgtttatgc aggcaccgga 1260
cgctaa 1266
<210> 2
<211> 1446
<212> DNA
<213> 谷氨酸棒状杆菌(Corynebacterium glutamicum)
<400> 2
gtggactaca tttcgacgcg tgatgccagc cgtacccctg cccgcttcag tgatattttg 60
ctgggcggtc tagcaccaga cggcggcctg tacctgcctg caacctaccc tcaactagat 120
gatgcccagc tgagtaaatg gcgtgaggta ttagccaacg aaggatacgc agctttggct 180
gctgaagtta tctccctgtt tgttgatgac atcccagtag aagacatcaa ggcgatcacc 240
gcacgcgcct acacctaccc gaagttcaac agcgaagaca tcgttcctgt caccgaactc 300
gaggacaaca tttacctggg ccacctttcc gaaggcccaa ccgctgcatt caaagacatg 360
gccatgcagc tgctcggcga acttttcgaa tacgagcttc gccgccgcaa cgaaaccatc 420
aacatcctgg gcgctacctc tggcgatacc ggctcctctg cggaatacgc catgcgcggc 480
cgcgagggaa tccgcgtatt catgctgacc ccagctggcc gcatgacccc attccagcaa 540
gcacagatgt ttggccttga cgatccaaac atcttcaaca tcgccctcga cggcgttttc 600
gacgattgcc aagacgtagt caaggctgtc tccgccgacg cagaattcaa aaaagacaac 660
cgcatcggtg ccgtgaactc catcaactgg gcacgcctta tggcacaggt tgtgtactac 720
gtttcctcat ggatccgcac cacaaccagc aatgaccaaa aggtcagctt ctccgtacca 780
accggcaact tcggtgacat ttgcgcaggc cacatcgccc gccaaatggg acttcccatc 840
gatcgcctca tcgtggccac caacgaaaac gatgtgctcg acgagttctt ccgtaccggc 900
gactaccgag tccgcagctc cgcagacacc cacgagacct cctcaccttc gatggatatc 960
tcccgcgcct ccaacttcga gcgtttcatc ttcgacctgc tcggccgcga cgccacccgc 1020
gtcaacgatc tatttggtac ccaggttcgc caaggcggat tctcactggc tgatgacgcc 1080
aactttgaga aggctgcagc agaatacggt ttcgcctccg gacgatccac ccatgctgac 1140
cgtgtggcaa ccatcgctga cgtgcattcc cgcctcgacg tactaatcga tccccacacc 1200
gccgacggcg ttcacgtggc acgccagtgg agggacgagg tcaacacccc aatcatcgtc 1260
ctagaaactg cactcccagt gaaatttgcc gacaccatcg tcgaagcaat tggtgaagca 1320
cctcaaactc cagagcgttt cgccgcgatc atggatgctc cattcaaggt ttccgaccta 1380
ccaaacgaca ccgatgcagt taagcagtac atagtcgatg cgattgcaaa cacttccgtg 1440
aagtaa 1446
Claims (9)
1.一种修饰的棒状杆菌属微生物,其特征在于,所述微生物相比于未修饰的微生物,其丙酮酸醌脱氢酶的活性降低或丧失,且所述微生物相比于未修饰的微生物具有增强的苏氨酸生产能力。
2.根据权利要求1所述的微生物,其特征在于,所述微生物体内丙酮酸醌脱氢酶的活性降低或丧失是通过降低编码丙酮酸醌脱氢酶基因的表达或敲除内源的编码丙酮酸醌脱氢酶的基因来实现的。
3.根据权利要求2所述的微生物,其特征在于,采用诱变、定点突变或同源重组的方法来降低编码丙酮酸醌脱氢酶基因的表达或敲除内源的编码丙酮酸醌脱氢酶的基因。
4.根据权利要求1所述的微生物,其特征在于,所述微生物与未修饰的微生物相比,其体内苏氨酸合成途径相关的酶的活性增强;
其中,所述与苏氨酸合成途径相关的酶选自天冬氨酸激酶、高丝氨酸脱氢酶、天冬氨酸半醛脱氢酶、天冬氨酸氨基转移酶、高丝氨酸激酶、苏氨酸合酶中的至少一种。
5.根据权利要求4所述的微生物,其特征在于,所述微生物为如下①~⑤中的任一种:
①丙酮酸醌脱氢酶活性降低或丧失且天冬氨酸激酶和/或高丝氨酸脱氢酶活性增强的微生物;
②丙酮酸醌脱氢酶活性降低或丧失且天冬氨酸激酶、高丝氨酸脱氢酶和/或天冬氨酸氨基转移酶活性增强的微生物;
③丙酮酸醌脱氢酶活性降低或丧失且天冬氨酸激酶、高丝氨酸脱氢酶和/或天冬氨酸半醛脱氢酶活性增强的微生物;
④丙酮酸醌脱氢酶活性降低或丧失且天冬氨酸激酶、高丝氨酸脱氢酶和/或高丝氨酸激酶活性增强的微生物;
⑤丙酮酸醌脱氢酶活性降低或丧失且天冬氨酸激酶、高丝氨酸脱氢酶和/或苏氨酸合酶活性增强的微生物。
6.根据权利要求4所述的微生物,其特征在于,所述微生物体内苏氨酸合成途径相关的酶的活性的增强是由选自以下1)~6),或任选的组合实现的:
1)通过导入具有所述酶的编码基因的质粒而增强;
2)通过增加染色体上所述酶的编码基因的拷贝数而增强;
3)通过改变染色体上所述酶的编码基因的启动子序列而增强;
4)通过将强启动子与所述酶的编码基因可操作地连接而增强;
5)通过对酶的氨基酸序列进行改变而增强;
6)通过对编码酶的核苷酸序列进行改变而增强。
7.根据权利要求1-5任一项所述的微生物,其特征在于,所述微生物为谷氨酸棒状杆菌(Corynebacterium glutamicum)。
8.产苏氨酸菌株的构建方法,其特征在于,所述方法包括:
A、弱化具有氨基酸生产能力的棒杆菌中编码丙酮酸醌脱氢酶的基因,获得基因弱化菌株;所述弱化包括敲除或降低丙酮酸醌脱氢酶编码基因的表达;和/或
B、增强步骤A基因弱化菌株中与苏氨酸合成途径相关的酶,获得酶活增强菌株;
所述增强的途径选自以下1)~5),或任选的组合:
1)通过导入具有所述酶的编码基因的质粒而增强;
2)通过增加染色体上所述酶的编码基因的拷贝数而增强;
3)通过改变染色体上所述酶的编码基因的启动子序列而增强;
4)通过将强启动子与所述酶的编码基因可操作地连接而增强;
5)通过对酶的氨基酸序列进行改变而增强;
其中,所述与苏氨酸合成途径相关的酶选自天冬氨酸激酶、高丝氨酸脱氢酶、天冬氨酸半醛脱氢酶、天冬氨酸氨基转移酶、高丝氨酸激酶、苏氨酸合酶中的至少一种。
9.一种生产苏氨酸的方法,其特征在于,所述方法包括如下步骤:
a)培养权利要求1-7任一项所述的微生物,以获得所述微生物的培养物;
b)从步骤a)中获得的所述培养物中收集所产生的苏氨酸。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210112879.3A CN116555134A (zh) | 2022-01-29 | 2022-01-29 | 产苏氨酸菌株的构建方法 |
PCT/CN2022/143762 WO2023142881A1 (zh) | 2022-01-29 | 2022-12-30 | 产苏氨酸菌株的构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210112879.3A CN116555134A (zh) | 2022-01-29 | 2022-01-29 | 产苏氨酸菌株的构建方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116555134A true CN116555134A (zh) | 2023-08-08 |
Family
ID=87470505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210112879.3A Pending CN116555134A (zh) | 2022-01-29 | 2022-01-29 | 产苏氨酸菌株的构建方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116555134A (zh) |
WO (1) | WO2023142881A1 (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005045301A1 (de) * | 2005-09-22 | 2007-04-05 | Degussa Ag | Verfahren zur Herstellung von organisch-chemischen Verbindungen unter Verwendung coryneformer Bakterien |
JP2009095237A (ja) * | 2006-02-02 | 2009-05-07 | Ajinomoto Co Inc | L−アミノ酸の製造法 |
CN113322218B (zh) * | 2020-02-28 | 2022-11-22 | 廊坊梅花生物技术开发有限公司 | 重组谷氨酸棒杆菌及生产l-苏氨酸的方法 |
-
2022
- 2022-01-29 CN CN202210112879.3A patent/CN116555134A/zh active Pending
- 2022-12-30 WO PCT/CN2022/143762 patent/WO2023142881A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023142881A1 (zh) | 2023-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6679803B2 (ja) | 新規プロモーター及びその用途 | |
CN113322218B (zh) | 重组谷氨酸棒杆菌及生产l-苏氨酸的方法 | |
CN110699310B (zh) | 一种四氢嘧啶高产谷氨酸棒杆菌及其应用 | |
CN118165903A (zh) | 产l-苏氨酸的基因工程菌及其应用 | |
JP7350994B2 (ja) | 新規なプロモーター及びそれを用いた標的物質生産方法 | |
CN116555134A (zh) | 产苏氨酸菌株的构建方法 | |
CN116622596A (zh) | 一种修饰的棒状杆菌属微生物及其构建方法与在生产苏氨酸中的应用 | |
KR102377745B1 (ko) | 신규 프로모터 및 이의 용도 | |
CN116536226A (zh) | 产苏氨酸工程菌的构建方法 | |
CN116622599A (zh) | 高产苏氨酸菌株的构建方法 | |
CN116622597A (zh) | 高产苏氨酸工程菌的构建方法 | |
CN116555135A (zh) | 高产苏氨酸基因工程菌的构建方法 | |
CN116536227A (zh) | 一种生产苏氨酸的修饰的棒状杆菌属微生物及其构建方法与应用 | |
CN116555130A (zh) | 产苏氨酸基因工程菌的构建方法 | |
WO2023151406A1 (zh) | 苏氨酸生产菌株的构建方法 | |
CN116606785A (zh) | 一种修饰的棒状杆菌属微生物及其应用与构建方法 | |
CN116555251A (zh) | 一种生产苏氨酸的重组微生物及其应用 | |
WO2023151407A1 (zh) | 苏氨酸生产菌株的构建方法 | |
CN115029289B (zh) | 高产l-苏氨酸的基因工程菌及其构建方法与应用 | |
CN116555136A (zh) | 一种修饰的棒状杆菌属微生物及其构建方法与应用 | |
CN116555132A (zh) | 一种修饰的棒状杆菌属微生物及其生产苏氨酸的应用和构建方法 | |
CN116555365A (zh) | 修饰的棒状杆菌属微生物及其构建方法和应用 | |
CN116606786A (zh) | 一种生产苏氨酸的重组微生物及其构建方法和应用 | |
CN116536310A (zh) | 启动子、产苏氨酸重组微生物及其应用 | |
CN116555137A (zh) | 一种苏氨酸生产菌株及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |